Disc Medicine已顺利完成针对红细胞生成性原卟啉症（EPP）的研究药物Bitopertin的三期临床试验——Apollo试验的患者招募工作。这一关键里程碑标志着该药物临床开发进入新阶段，为后续数据收集和分析奠定基础。
红细胞生成性原卟啉症是一种罕见的光敏感性皮肤病，Bitopertin作为一种创新疗法，其三期临床试验的推进备受行业关注。此次顺利完成患者招募，展现了Disc Medicine在罕见病治疗领域的执行效率。
Disc Medicine已顺利完成针对红细胞生成性原卟啉症（EPP）的研究药物Bitopertin的三期临床试验——Apollo试验的患者招募工作。这一关键里程碑标志着该药物临床开发进入新阶段，为后续数据收集和分析奠定基础。
红细胞生成性原卟啉症是一种罕见的光敏感性皮肤病，Bitopertin作为一种创新疗法，其三期临床试验的推进备受行业关注。此次顺利完成患者招募，展现了Disc Medicine在罕见病治疗领域的执行效率。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.